A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Fondazione Italiana Linfomi - ETS
N.N. Petrov National Medical Research Center of Oncology
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
Institute of Hematology & Blood Diseases Hospital, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University of Nebraska
Henan Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
National Institutes of Health Clinical Center (CC)
Czech Lymphoma Study Group
Samsung Medical Center
Eisai Inc.
Acrotech Biopharma Inc.
Zhejiang Cancer Hospital
Chipscreen Biosciences, Ltd.
Lymphoma Study Association
Southwest Hospital, China
Sun Yat-sen University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center